Communiqués Denali Therapeutics Inc.

Actions

DNLI

US24823R1059

Temps réel estimé Cboe BZX Autres places de cotation 16:55:26 16/07/2024			Varia. 5j.	Varia. 1 janv.
23,62 ^USD	+1,24 %		+12,98 %	+10,34 %

13/06	Pliant Therapeutics, Inc. nomme Steve Krognes à son conseil d'administration	CI
03/06	La thérapie de remplacement enzymatique de Denali Therapeutics choisie pour le programme pilote START de la FDA ; les actions augmentent	MT

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer	13/06	AQ
Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies	03/06	GL
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights	07/05	GL
Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial	01/05	GL
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences	09/04	AQ
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights	27/02	GL
Denali Therapeutics Announces $500 million Private Placement Equity Financing	27/02	GL
Denali Therapeutics Announces $500 million Private Placement Equity Financing	27/02	AQ
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™	07/02	GL
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™	07/02	AQ
Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™	01/02	GL
Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™	01/02	AQ
Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases	08/01	GL
Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases	08/01	AQ
Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights	07/11	GL
MOMENTUM IN ALZHEIMER'S RESEARCH GUIDED BY THE BIOLOGY OF AGING TO BE HIGHLIGHTED IN SESSION MODERATED BY ALZHEIMER'S DRUG DISCOVERY FOUNDATION AT 2023 CLINICAL TRIALS ON ALZHEIMER'S DISEASE CONFERENCE	18/10/23	AQ
Metachromatic Leukodystrophy Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)	09/10/23	AQ
ProFound Therapeutics Expands Leadership Team with Appointment of Klaus Urbahns as Chief Scientific Officer	26/09/23	AQ
Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023	30/08/23	GL
ALLTRNA EXPANDS LEADERSHIP TEAM WITH APPOINTMENTS OF CHIEF SCIENTIFIC OFFICER AND CHIEF TECHNOLOGY OFFICER	16/08/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Denali Therapeutics Inc.

Actions

DNLI

US24823R1059

Communiqués

Filtres